Open Trial of Escitalopram Treatment for Male Subjects With Posttraumatic Stress Disorder
NCT ID: NCT01024140
Last Updated: 2009-12-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
16 participants
INTERVENTIONAL
2003-02-28
2004-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
A secondary aim is to determine whether treatment with escitalopram increases plasma allopregnanolone levels in patients with PTSD and if increases in allopregnanolone levels are correlated with treatment efficacy.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Escitalopram
Flexible dose (5-20mg/day) of escitalopram monotherapy.
Escitalopram
Subjects were started on 5mg escitalopram. Medication was increased as tolerated in weekly 2.5, 5 or 10 mg increments, until a maximally tolerated dosage or a clinical response was achieved. The final dosage ranged from 5 to 20 mg/day.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Escitalopram
Subjects were started on 5mg escitalopram. Medication was increased as tolerated in weekly 2.5, 5 or 10 mg increments, until a maximally tolerated dosage or a clinical response was achieved. The final dosage ranged from 5 to 20 mg/day.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Prominent suicidal or homicidal ideation.
* History of alcohol abuse/dependence within the past 3 months.
* History of drug abuse/dependence within the past 6 months.
* Subjects who plan to start a new form of psychotherapy during the protocol.
* History of sleep apnea, neurological disorder and/or current systemic illness affecting central nervous system function.
* History of myocardial infarction in the past year.
* Subjects on antipsychotic medications, systemic steroid medication, antidepressants, mood stabilizers, antianxiety medication, or benzodiazepines within the past 2 weeks.
* Use of Citalopram or Escitalopram within the past 6 months.
20 Years
60 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Northern California Institute of Research and Education
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
UCSF / VAMC / NCIRE
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Thomas C Neylan, MD
Role: PRINCIPAL_INVESTIGATOR
UCSF / VAMC / NCIRE
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NEY-608
Identifier Type: -
Identifier Source: org_study_id